Resistentie voor vismodegib bij de behandeling van het basaalcelcarcinoom

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The hedgehog pathway inhibitor vismodegib provides a
new treatment option for metastasized and locally advanced
basal cell carcinoma for which surgical excision or
radiotherapy is contraindicated. However, adverse events
frequently lead to discontinuation of therapy and development
of tumor resistance is quite common. In the
future, combination therapy could reduce the occurrence
of tumor resistance.
Original languageDutch
Pages (from-to)550-552
Number of pages3
JournalNederlands Tijdschrift voor Dermatologie en Venereologie
Volume27
Issue number10
Publication statusPublished - Oct 2017

Cite this